PET Imaging With 89Zr-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
Our goal is to investigate the use of 89Zr-trastuzumab as a HER2 imaging agent to determine
which patients are likely to respond to targeted HER2 agents as single agent therapy. We are
proposing to perform a pilot study with goals of demonstrating the feasibility of imaging
breast cancer patients with 89Zr-trastuzumab-PET/MRI, evaluating the relationship between
tumor 89Zr-trastuzumab uptake and in vitro positivity of HER2, assessing the relationship
between 89Zr-trastuzumab uptake and response to HER2 therapy.